Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension
16 February 2022 – Walder Wyss advised Adjuvant Capital, a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies, on the series B financing of Memo Therapeutics AG.
Memo Therapeutics is an innovator in the field of antibody discovery and development.
The proceeds will be used to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients through Phase 2 clinical development.
The Walder Wyss team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and included Michelle Bruni (Senior Associate, Corporate/M&A and Tax), Karina Tschon (Associate, Corporate/M&A and Venture Capital) and Bojan Momic (Associate, Corporate/Employment).